Feedback
European Shorting
My Portfolios
Browse Gurus
Print
Email
Bookmark
Stereotaxis designs manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to allow physicians to navigate catheters guidewires and stent delivery devices through the blood vessels and chambers of the heart to treatment sites. Stereotaxis Inc. has a market cap of $182.1 million; its shares were traded at around $4.33 with and P/S ratio of 4.5.
Recent Trades of Stereotaxis Inc. by CEO:
- Buy: President & CEO Michael P Kaminski bought 2,300 shares of STXS stock on 06/04/2009 at the average price of $4.44; the price of the stock has decreased by 2.48% since.
Recent Trades of Stereotaxis Inc. by Directors and Officers:
- Buy: Director, 10% Owner Christopher D Alafi bought 15,000 shares of STXS stock on 05/29/2009 at the average price of $3.45; the price of the stock has increased by 25.51% since.
- Buy: Director, 10% Owner Fred A Middleton bought 27,792 shares of STXS stock on 05/26/2009 at the average price of $3.45; the price of the stock has increased by 25.51% since.
- Buy: Director, 10% Owner Christopher D Alafi bought 50,000 shares of STXS stock on 05/14/2009 at the average price of $3.48; the price of the stock has increased by 24.43% since.
- Buy: Director David Benfer bought 3,500 shares of STXS stock on 03/13/2009 at the average price of $3.79; the price of the stock has increased by 14.25% since.
- Buy: Director, 10% Owner Fred A Middleton bought 1,012,130 shares of STXS stock on 12/29/2008 at the average price of $4.64; the price of the stock has decreased by 6.68% since.
Subscribe RSS
RSS